Alle Storys
Folgen
Keine Story von Isotechnika Inc. mehr verpassen.

Isotechnika Inc.

Isotechnika Receives Approval From Polish Competent Authority for Pivotal Phase 3 Psoriasis Clinical Trial

Edmonton, Canada (ots/PRNewswire)

- Trades on Toronto Stock Exchange - (TSX:ISA)
Isotechnika Inc. announced today that the Company received
approval from  the Polish Competent Authority for participation in
the ongoing Phase 3  European/Canadian clinical trial. This trial
investigates the use of ISA247  in patients suffering from moderate
to severe psoriasis. The Company  previously received approval from
the German Competent Authority and Health  Canada to commence the
trial. At present, a total of 283 patients have been  enrolled in
Germany and Canada.
"The addition of twelve clinical trial sites in Poland allows
others to  gain experience with ISA247 for the treatment of psoriasis
and further  broadens our investigator base. Addition of these sites,
to the twenty-nine  sites already established in Germany and Canada,
should facilitate us meeting  our expected recruitment timelines for
this trial," stated Dr. Randall  Yatscoff, Isotechnika's President &
CEO. "Patient enrolment in Poland is  expected to commence
immediately."
Phase 3 European/Canadian Trial Design
The Phase 3 European/Canadian psoriasis trial (ESSENCE) will be
performed  at forty-one clinical centers in Canada, Germany, and
Poland. The 24-week  trial is being conducted as a randomized, orally
administered placebo and cyclosporine controlled trial. To maximize
the benefit to patients enrolled  in the placebo group, all patients
randomized to the placebo group will  receive active treatment with
ISA247 beginning after 12 weeks of placebo  dosing.
To determine successful completion of the trial, the following
efficacy parameters will be measured: Static Physician's Global
Assessment (SPGA)  scores, Psoriasis Area and Severity Index (PASI)
scores. Safety parameters  will also be monitored by measuring the
prevalence of adverse events,  including altered kidney function.
About Isotechnika Inc.
Edmonton-based Isotechnika Inc. is an international
biopharmaceutical  company focused on the discovery and development
of novel immunosuppressive  therapeutics that are designed to offer
advantages over other currently  available treatments while offering
therapeutic choices to clinicians.  Isotechnika looks to become the
market leader of drug therapies for  indications such as
transplantation of solid organs and treatment of  autoimmune
disorders such as psoriasis.
There is a significant unmet medical need in both solid organ
transplantation and autoimmune disease. It is estimated that the
market  potential far exceeds $1 billion annually in sales for
calcineurin inhibitors  such as ISA247.
Isotechnika's lead drug, ISA247, has successfully completed a
Phase 3  Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is  currently being investigated in a combined
Phase 3 European/Canadian  psoriasis trial and a Phase 2b North
American trial for the prevention of  kidney graft rejection. One of
our partners, Lux Biosciences, has received  permission from the
regulatory bodies in Austria, Canada, France, Germany,  India, the
United Kingdom and the United States to investigate ISA247 in  three
separate pivotal Phase 2/Phase 3 trials for the treatment of non-
infectious uveitis and as a maintenance therapy in uveitis.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found  at www.isotechnika.com.
Partnerships with Isotechnika Inc.
Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche  on April 9, 2002, which licensed the worldwide rights to
develop and  commercialize ISA247 for all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of  ISA247 and TAFA93 specifically with drug eluting medical
devices for the non- systemic treatment of vascular, cardiovascular,
target vessel and tissue  disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April  25, 2006, granting Isotechnika the option to obtain an
exclusive license to  develop and commercialize conjugates consisting
of Cellgate's patented  transporter technology for the topical
delivery of ISA247 in patients  suffering all forms of psoriasis.
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug,  ISA247, for the treatment and prophylaxis of all ophthalmic
diseases.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its  products, the Company's expectations regarding the
issuance of additional  patents and the Company's ability to protect
its intellectual property,  involve known and unknown risks and
uncertainties, which could cause the  Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the  availability of
funds and resources to pursue research and development  projects, the
ability to economically manufacture its products, the potential  of
its products, the success and timely completion of clinical studies
and  trials, the Company's ability to successfully commercialize its
products, the  ability of the Company to defend its patents from
infringement by third  parties, and the risk that the Company's
patents may be subsequently shown to  be invalid or infringe the
patents of others. Investors should consult the  Company's quarterly
and annual filings with the Canadian commissions for  additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on  forward-looking statements.
www.isotechnika.com

Contact:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext. 247, Fax:
+1-780-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-487-1600 Ext. 243, Fax: +1-780-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com

Weitere Storys: Isotechnika Inc.
Weitere Storys: Isotechnika Inc.
  • 07.05.2007 – 12:06

    Isotechnika Announces Interim Three Month Data From Phase 2b Kidney Transplant Trial

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first 116 ...

  • 06.05.2007 – 20:51

    Advisory - Isotechnika to Announce Interim Three Month Data From Phase 2b Kidney Transplant Trial

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. will announce interim three month data from its Phase 2b kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Monday, May 7th at 6:00 a.m. ET/4:00 a.m. MT. The management team will provide a review of the Phase 2b kidney transplant trial via a live conference call on Monday, May 7th ...

  • 03.05.2007 – 15:20

    Isotechnika Selected for Oral Presentation at the American Transplant Congress

    Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika today announced that the Company has been selected to give an oral presentation during the American Transplant Congress in San Francisco, California. An overview of the latest Phase 2b kidney transplant trial (PROMISE) results will be presented during an oral ...